CYP4F2 Antibody

中文名稱：

CYP4F2兔多克隆抗體
貨號：

CSB-PA006451LA01HU
規格：

￥440
圖片：
IHC image of CSB-PA006451LA01HU diluted at 1:200 and staining in paraffin-embedded human kidney tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) CYP4F2 Polyclonal antibody
Uniprot No.：

P78329
基因名：

CYP4F2
別名：

CYP4F2Cytochrome P450 4F2 antibody; EC 1.14.14.1 antibody; 20-hydroxyeicosatetraenoic acid synthase antibody; 20-HETE synthase antibody; Arachidonic acid omega-hydroxylase antibody; CYPIVF2 antibody; Cytochrome P450-LTB-omega antibody; Docosahexaenoic acid omega-hydroxylase antibody; EC 1.14.14.79 antibody; Leukotriene-B(4) 20-monooxygenase 1 antibody; Leukotriene-B(4) omega-hydroxylase 1 antibody; EC 1.14.14.94 antibody; Phylloquinone omega-hydroxylase CYP4F2 antibody; EC 1.14.14.78 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Phylloquinone omega-hydroxylase CYP4F2 protein (268-373AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，CYP4F2 Antibody (CSB-PA006451LA01HU)，的標記方式是Non-conjugated。對于CYP4F2 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA006451LB01HU	CYP4F2 Antibody, HRP conjugated	ELISA
FITC	CSB-PA006451LC01HU	CYP4F2 Antibody, FITC conjugated
Biotin	CSB-PA006451LD01HU	CYP4F2 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:200-1:500

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, eicosanoids and vitamins. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of long- and very long-chain fatty acids. Displays high omega-hydroxylase activity toward polyunsaturated fatty acids (PUFAs). Participates in the conversion of arachidonic acid to omega-hydroxyeicosatetraenoic acid (20-HETE), a signaling molecule acting both as vasoconstrictive and natriuretic with overall effect on arterial blood pressure. Plays a role in the oxidative inactivation of eicosanoids, including both proinflammatory and anti-inflammatory mediators such as leukotriene B4 (LTB4), lipoxin A4 (LXA4), and several HETEs. Catalyzes omega-hydroxylation of 3-hydroxy fatty acids. Converts monoepoxides of linoleic acid leukotoxin and isoleukotoxin to omega-hydroxylated metabolites. Contributes to the degradation of very long-chain fatty acids (VLCFAs) by catalyzing successive omega-oxidations and chain shortening. Plays an important role in vitamin metabolism by chain shortening. Catalyzes omega-hydroxylation of the phytyl chain of tocopherols (forms of vitamin E), with preference for gamma-tocopherols over alpha-tocopherols, thus promoting retention of alpha-tocopherols in tissues. Omega-hydroxylates and inactivates phylloquinone (vitamin K1), and menaquinone-4 (MK-4, a form of vitamin K2), both acting as cofactors in blood coagulation.
基因功能參考文獻：
1. Epistatic interactions associated with susceptibility to coronary artery disease were found between rs9332978 of CYP4A11 and rs1558139 of CYP4F2. PMID: 29484037
2. The C/T genotype of the CYP4AF2 rs1558139 polymorphism might serve as a protective factor for male patients with hypertension in Asian populations, and CYP4AF2 rs2108622 may confer reduced genetic susceptibility to coronary heart disease. PMID: 29426278
3. Data suggests that expression of CYP4F2 is down-regulated in liver of mice with non-alcoholic fatty liver disease after high-fat/Western diet and in human hepatocyte cell line exposed to excess palmitic acid, oleic acid, or fructose. Two other genes are down-regulated, PPAR gamma and SREBP-1. (PPAR = peroxisome proliferator-activated receptor; SREBP-1 = sterol regulatory element-binding protein-1) PMID: 28628909
4. show that children on chronic warfarin therapy have low levels of vitamin K and vitamin K levels are linked to CYP4F2 genotype PMID: 28521079
5. impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation PMID: 27662649
6. CYP4F2 gene repression and a sustained vitamin E metabolism appear to be independent effects of ethanol toxicity in human hepatocytes PMID: 28062356
7. CYP4A1l rs9333025 GG and CYP4F2 rs2108622 GG two-loci interaction significantly increases the risk for IS and an elevated 20-HETE level. PMID: 26959478
8. This study provides data on VKORC1 and CYP4F2 variants among an indigenous Ghanaian population. PMID: 27938396
9. This meta-analysis indicated the impact of the CYP4F2 polymorphism on bleeding complications and over-anticoagulation in coumarin-treated patients failed to reach the level of statistical significance. PMID: 27052278
10. Did not find any association of the CYP4F2 gene rs2108622 polymorphism with hypertension. PMID: 26634476
11. Study showed that the V433M polymorphism in CYP4F2, responsible for epoxyeicosatrienoic acids synthesis, was an independent risk factor for post-transplant diabetes mellitus. PMID: 26483195
12. Bearing of two minor alleles of CYP4F2 missense variant modestly explains inter-ethnic differences of studied populations. CYP4F2*3 risk allele frequency of Roma was in higher range, and of Hungarians in lower range, compared with other world populations PMID: 26176903
13. CYP4F2 c.1297A polymorphism has a moderate effect on VKAs dose requirements in Slavic population from Central-Eastern Europe. PMID: 25042728
14. The frequency of CYP2C9, CYP4F2, and VKORC1 polymorphisms in Russian patients with thrombosis is comparable with other European ethnic groups. PMID: 24858991
15. To evaluate the associations between four single-nucleotide polymorphisms (SNPs) in CYP4A11 and CYP4F2 and ischemic stroke (IS) PMID: 25734770
16. Plasma VK1 and MK-4 concentrations are influenced by CYP4F2 genetic polymorphism but not associated with warfarin therapy in Japanese patients. CYP4F2 polymorphism is poorly associated with inter-individual variability of warfarin dosage requirement. PMID: 25747538
17. CYP4F2 gene polymorphism might increase the risk of ischemic stroke in the Chinese population. PMID: 25730002
18. Around 42.5% of the overall interindividual variability in warfarin dose requirements was explained : VKORC1 genotype accounted for 29.6%, CYP2C9 genotype for 4.3%, age for 3.6%, the CYP4F2 genotype for 3.3%, and CAR/HNF4alpha (rs2501873/rs3212198) for 1.7% PMID: 25356900
19. Although initial studies on CYP4F2 were focused on its role as a regulator of LTB4 and 20-HETE, current investigations focus on how variants of CYP4F2 affect warfarin drug dosing and safety PMID: 25370453
20. CYP2C19*2*2 versus *1*1 and *1*2 genotype (OR: 11.625; 95% CI: 3.498-38.633), CYP4F2 AA versus GA and GG genotype (OR: 3.532; 95% CI: 1.153-10.822) were associated with early stent thrombosis. PMID: 25712182
21. Polymorphisms in CYP4F2 gene is associated with warfarin dose changes in different race during venous thromboembolism. PMID: 26024874
22. Our study of 250 cases of major bleeding found that CYP2C9*3 (OR: 2.05, 95% CI [1.04,4.04]), but not CYP2C9*2, VKORC1 or CYP4F2, increased the risk of major bleeding PMID: 25521356
23. Maintenance of lower blood pressure after weight loss is more difficult for carriers of the CYP4F2 G1347A polymorphism and may be related to increased arterial stiffness and increased 20-HETE synthesis. PMID: 24984178
24. VKORC1 variant (-1639A) was shown to be prevalent amongst Tibeto-Burmans, whereas CYP2C9 (R144C, I359L) and CYP4F2 (V433M) variants were observed in considerable variability amongst Indo-Europeans PMID: 25155935
25. The allele frequency for CYP4F2 1347 G>A is 43.14 in north Indians but did not have significant bearing on the maintenance dose of acenocoumarol oral anticoagulant in cardiac valve replacement patients. PMID: 24927344
26. distribution of INR was influenced by variants in CYP4F2 rs2108622, CYP2C9*3, rs9332230, VKORC1 1173C>T, -1639G>A, rs55894764, ABCB1 rs2032582, rs1128503, rs1045642 and F5 rs6025, age, smoking and concomitant drugs PMID: 24911077
27. In addition to VKORC1 and CYP2C9, CYP4F2 gene has a slight but significant role in reaching INR >2.5 during the first weeks of acenocoumarol therapy. PMID: 24956252
28. CYP4F2 gene polymorphisms were associated with the risk of CHD in Chinese population. PMID: 24886380
29. The effect of CYP2C9, VKORC1 and CYP4F2 polymorphism and of clinical factors on warfarin dosage during initiation and long-term treatment after heart valve surgery. PMID: 23677510
30. CYP4F2-derived 20-HETE mediates EC proliferation. PMID: 24668751
31. CYP4F2 1297T allele was associated with mild (Child-Pugh class A-B) cirrhosis. PMID: 24319743
32. High CYP omega-hydroxylase expression is asosciated with pancreatic ductal adenocarcinoma. PMID: 23846787
33. CYP2C9 (p=0.004) and VKORC1 (p=0.02) variant carriers required lower cumulative doses, and CYP4F2 carriers required higher doses (p=0.04) of warfarin to reach an INR of 2.0 PMID: 24029542
34. The study identifies common polymorphisms limked to warfarin resistance and sensitivity in the VKORC1, CYP2C9 and CYP4F2 genes. PMID: 23726967
35. CYP3A4 and CYP4F2 single nucleotide polymorphism have effects on stable phenprocoumon and acenocoumarol maintenance doses PMID: 23510058
36. Microsomal menaquinone-4 omega-hydroxylation activities correlated with the CYP4F2 V433M genotype but not the CYP4F11 D446N genotype PMID: 24138531
37. CYP4F2 genetic variation did not affect the pharmacokinetics and pharmacodynamics of low-dose warfarin. PMID: 22855348
38. Multiple regression analysis in the Hispanic-American cohort revealed that each CYP4F2 433M allele was associated with a 22% increase in warfarin maintenance dose (p = 0.019). PMID: 23215885
39. These result show that single nucleotide polymorphisms of CYP4F2 exerted no significant effects on baseline coagulation activity assessed by fully carboxylated plasma normal prothrombin (NPT) PMID: 23018470
40. Functional polymorphisms in CYP2C9, CYP4F2 and VKORC1 genes affect response to warfarin dose in an admixed Omani patient cohort. PMID: 22854539
41. Dose variability in CYP4F2 genotypes is attributable to both warfarin clearance and sensitivity differences in Korean patients with mechanical heart valves. PMID: 22549502
42. Our results show that the CYP4F2 p.V433M polymorphism is associated with interindividual variability in response to coumarin drugs PMID: 23132553
43. Found the frequency of the CYP4F2 rs2108622 C allele in individuals with implanted mechanical valve prostheses was 79.5% and T-allele frequency was 20.5%.TT-homozygous individuals required a 0.56 mg/day higher dose of warfarin than their CC counterparts. PMID: 23013706
44. The multiple linear regression model including VKORC1-1639G>A, CYP2C9, CYP4F2 and clinical factors (body surface area (BSA) and age) could explain 42 % of the variance in the warfarin maintenance dose. PMID: 22528326
45. Report algorithm predicting warfarin dose in Chinese Han patients with valvular atrial fibrillation based on CYP4F2/CYP2C9/VKORC1 polymorphisms. PMID: 22534826
46. The initial positive association of the CYP4F2 V433M polymorphism with components of metabolic syndrome and MetS itself, found in MDC-CVA, was partially denied in another large cohort. PMID: 22484021
47. The present study indicated that VKORC1, CYP4F2, and CYP2C9 genotypes and interacting drugs had a significant impact on the warfarin maintenance dose in Chinese patients with heart valve replacement PMID: 22198820
48. The researchers evaluated the prevalence of the CYP4F2 polymorphism in a population of Omanis. PMID: 22452429
49. Quantitative PCR assays for VKORC1, CYP4F2, GGCX and CALU identified two copies in all populations. PMID: 22188360
50. Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione PMID: 21883387
顯示更多

收起更多
相關疾病：

Coumarin resistance (CMRES)
亞細胞定位：

Microsome membrane; Peripheral membrane protein. Endoplasmic reticulum membrane; Peripheral membrane protein.
蛋白家族：

Cytochrome P450 family
組織特異性：

Liver. Also present in kidney: specifically expressed in the S2 and S3 segments of proximal tubules in cortex and outer medulla.
數據庫鏈接：

HGNC: 2645

OMIM: 122700

KEGG: hsa:8529

STRING: 9606.ENSP00000221700

UniGene: Hs.558423

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human